Abbott Labs Guidance Cut 2026: What the Exact Sciences Acquisition Means for ABT Stock

# Abbott Labs Guidance Cut 2026: What the Exact Sciences Acquisition Means for ABT Stock

> **Quick answer:** Abbott Labs beat Q1 2026 EPS estimates ($1.15 vs. $1.14 expected) but cut its full-year guidance to $5.38–$5.58 — below the $5.62 Wall Street consensus — because the $21 billion Exact Sciences acquisition carries a 20-cent-per-share dilution drag in 2026. ABT shares hit a 52-week low near $96.72 on April 17. Every major analyst maintained a Buy rating, but all four cut price targets to $120. This is a short-term integration cost, not a business deterioration — but the market is pricing in the pain now.

Abbott Labs guidance cut 2026 Exact Sciences acquisition headlines rocked investors on April 17, sending ABT stock to its lowest level in a year despite a quarter that, by every operational measure, came in ahead of expectations. Understanding why requires separating two very different stories: a strong business and an expensive strategic bet.

This article is for informational purposes only and does not constitute financial advice. Consult a qualified financial advisor for personal financial decisions.

## What Happened: Abbott Beat Q1 But Cut the Year

Abbott Laboratories reported first-quarter 2026 results on April 16, 2026, after market close. The headline numbers were fine — better than fine, actually.